首页|Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic:new perspectives and insights

Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic:new perspectives and insights

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Myocardial injury is one of the most common comorbidity in SARS-CoV-2 infected patients,and has poor prognosis.However,the incidence of myocardial injury in patients with SARS-CoV-2 infection has not been sufficiently investigated during the Omicron wave.We conducted a retrospective study of 2690 patients with confirmed SARS-CoV-2 Omicron infection from Tongji Hospital.The results indicated that the myocardial injury accounted for 30.8％of the total patients with SARS-CoV-2 infection and was associated with higher in-hospital mortality than those without injury before and after propensity score matching(PSM)[adjusted hazard ratio(HR),10.61;95％confidence interval(CI),7.76-14.51;P＜0.001;adjusted HR,2.70;95％CI,1.86-3.93;P＜0.001;respectively].Further,the levels of cytokines(IL-1β,IL-6,IL-10,and TNF-α)in patients with myocardial injury were higher than those without injury,and the higher levels of cytokines in the myocardial injury group were associated with increased mortality.Administration of angiotensin-converting enzyme inhibitors or angio-tensin receptor blockers(ACEI/ARB)could significantly reduce the mortality in patients with myocardial injury(adjusted HR,0.52;95％CI,0.38-0.71;P＜0.001).Additionally,the level of angiotensin II increased in patients with SARS-CoV-2 infection was even higher in myocardial injury group compared to those without injury.Collectively,the study summarized the clinical characteristic and outcome of SARS-CoV-2 infected patients with myocardial injury during the Omicron wave in China,and validated the protective role of ACEI/ARB in improving the survival of those with myocardial injury.

COVID-19OmicronMyocardial injuryIn-hospital mortalityCytokine storm

Wu He、Ke Xu、Li Ni、Junfang Wu、Yuxuan Zhang、Kun Miao、Luyun Wang、Dao Wen Wang

展开 >

Division of Cardiology,Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China

Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders,Wuhan,430030,China

National Key Research and Development Program of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaTop-Notch Talent Program of Hubei Province and Tongji HospitalHubei Provincial Key Research and Developmental ProgramHubei Provincial Natural Science Foundation of China

2022YFC3400700822410348237039731971358U22A20266C-00522021YBJRC0052022BCA0372017CFB536

2023

10.1016/j.virs.2023.10.005

中国病毒学
中国科学院武汉病毒研究所，中国微生物学会

中国病毒学

CSTPCDCSCD
影响因子：0.393
ISSN：1674-0769
年,卷(期)：2023.38(6)
  • 45